This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Sanofi-Aventis's Tender Offer for Genzyme
Eades, Kenneth M.; Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1716-EFinanceIn October 2010, Henri Termeer, the chairman and CEO of Genzyme, received a letter from the CEO of Sanofi-Aventis announcing its intention to commence a tender offer for Genzyme. Termeer thought the offer undervalued Genzyme, given the number of promising new drugs in the company’s pipeline and the success of its current drug portfolio. The case focuses on the strategic and financial considerations of a large corporate acquisition. To estimate Ge...Starting at €8.20
-
Negociando una operación de capital riesgo (II): Estructuración del acuerdo e instrumentos contractuales
Segurado, Juan Luis; Roure, JuanTechnical Note EN-11Entrepreneurship, FinanceCuando se trata de estructurar las operaciones, y con independencia de su naturaleza, los inversores de capital riesgo buscan, fundamentalmente, maximizar su retorno, minimizar sus riesgos financieros y cubrirse frente a los posibles conflictos de interés que pueden surgir con los gestores de las compañías en las que invierten. Para ello, negocian la incorporación ?en los acuerdos de inversión? de una serie de mecanismos de control y de asignació...Starting at €8.20
-
The Sanofi-Aventis Acquisition of Genzyme: Contingent Value Rights
Matos, Pedro; Aleyev, Dmitriy; Xu, ChongCase DARDEN-F-1715-EFinanceThis case is designed for MBA students in M&A or derivatives courses. In January 2011, Sanofi-Aventis was finalizing its offer terms for acquiring Genzyme. The M&A valuation disputes were about the market potential of alemtuzumab, a drug in Genzyme’s pipeline, and how quickly Genzyme could resolve some of its manufacturing issues. To bridge the gap in their estimates, advisers had suggested an up-front cash payment and a contingent value right (C...Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide? - Teaching Note
Eades, Kenneth M.; Matos, PedroTeaching Note DARDEN-F-1660TN-EFinanceTeaching note for product F-1660Starting at €0.00
-
Metodología PDCA para la mejora contínua de los procesos
Moñino, M.; Roure, JuanTechnical Note PN-328Service and Operations ManagementEl objetivo de esta nota técnica es explicar la metodología PDCA («Plan, Do, Check, Act») usada en Hewlett-Packard para la mejora continua de los procesos. Su propósito es que exista una sistemática en la resolución de problemas o en la mejora de procesos, a fin de asegurar que se direccionan las causas de raíz, proporcionando, en definitiva, el camino más corto y más seguro para la resolución del problema o mejora pretendida.Starting at €8.20
-
Introducción a la gestión de procesos
Moñino, M.; Roure, JuanTechnical Note PN-327Service and Operations ManagementEl objetivo de esta nota técnica es dar guías para abordar la gestión de procesos en una empresa, reflexionando sobre las siguientes preguntas: ¿Por qué es importante gestionar por procesos? ¿Cuáles son las actividades que ocurren? ¿Cómo inventariarlas? ¿Cuáles son las más importantes? ¿Cómo gestionarlas eficaz y eficientemente? ¿Cómo documentarlas y medirlas? ¿Cómo mejorarlas?Starting at €8.20
-
Dominion Gas Holdings, LLC-Anticipatory Interest Rate Hedging
Matos, Pedro; Maiden, Stephen E.Case DARDEN-F-1754-EFinanceThe case examines interest rate risk management at a U.S. utility company, Dominion Gas Holdings. In November 2012, as part of its new financing plan, it wanted to hedge the interest rate risk involved with the company’s 2013 planned issuance of $1 billion in debt. While the coupon rates for the planned debt were unknown as of November 2012, the company wanted to lock in its financing costs one year ahead since interest rates were at historically...Starting at €8.20
-
Genzyme and Relational Investors: Science and Business Collide?
Eades, Kenneth M.; Matos, Pedro; Green, RickCase DARDEN-F-1660-EFinanceThe chairman and CEO of the Genzyme Corporation, one of the country’s top five biotechnology firms, has received a phone call requesting a meeting with the cofounder and principal of a large activist investment fund that now has a 2.6% stake in his company. Before meeting with him, the CEO is aware that he needs a strategy for dealing with this “activist” investor with a track record of forcing out CEOs.Starting at €8.20
-
La gestión estratégica de los procesos
Moñino, M.; Rodríguez Badal, Miguel Ángel; Roure, JuanTechnical Note PN-395Service and Operations ManagementSe comentan los cambios que representan pasar de la gestión tradicional de procesos a la nueva Gestión por Procesos o Gestión Estratégica de Procesos.Starting at €8.20
-
The Barceló Group: Entrepreneurial Spirit and Corporate Governance
Roure, Juan; Segurado, Juan LuisCase E-206-ECorporate Governance, EntrepreneurshipThis case, based on the IESE case E 99 E, deals first of all with entrepreneurial experience and the process of family transition that led to the development and successful growth of the Barceló Group, one of the most important family-owned hotel chains in Spain and, secondly, the development of corporate and family governance structures and their role in the group's successful growth.Starting at €8.20